137.55 -0.15 (-0.11%)
After hours: 4:52PM EDT
|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||137.48 - 138.67|
|52 Week Range||113.43 - 159.85|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.62|
|Expense Ratio (net)||0.57%|
Biotechnology stocks and sector-related exchange traded funds stood out on Tuesday after a U.S. District Court overruled President Donald Trump’s wishes to require drugmakers list prices on television ...
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
We have presented a bunch of top-performing ETFs of the 10-year bull market that will continue to outperform in the coming months given that these have a Zacks ETF Rank 1 (Strong Buy) or 2 (Buy).
Though volatility may persist this year, Churchill Management Group says moneymaking opportunities may exist even for cautious stock market investors.
Biotech ETFs allow investors to buy into a basket of biotech stocks, rather than trying to select specific winners. The best biotech ETFs are diverse, with less volatility.
Exelixis stock rose from $13.87 at the close of markets on October 31, 2018, to reach $20.31 at the close of market on November 30, 2018, a ~46% increase over the last month. Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29, 2018. Exelixis stock experienced solid growth after the company released its third-quarter financial results on November 1, 2018.
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.
Exelixis reported revenues of $625.2 million in the first nine months of this year compared to $332.4 million in the same period the prior year. In the third quarter, Exelixis generated revenues of $162.9 million from product sales compared to $96.4 million in the third quarter of 2017, reflecting ~69% YoY growth. Exelixis generated $62.5 million in collaboration revenues in the third quarter compared to $56.1 million in the third quarter of 2017.
As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.
Alkermes (ALKS) reported its third-quarter financial results on October 23. It generated net revenues of $248.7 million compared to $217.4 million in the third quarter of 2017. That was a 14% YoY (year-over-year) growth.
Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.
Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.
In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million. Kalydeco, Orkambi, and Symdeko saw revenue of $253.0 million, $311.0 million, and $186.0 million, respectively, in Q2 2018, compared with $250.0 million, $354.0 million, and $34.0 million, respectively, in Q1 2018. Vertex’s revenue growth could boost the First Trust NYSE Arca Biotechnology Index ETF (FBT), of which Vertex comprises ~3.33%.
In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).
Smaller is better for First Trust NYSE Arca Biotechnology Index Fund, which has become one of the top ETFs by using a concentrated portfolio.
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.